This provider's $76.0M in total Medicare payments ranks in the 99th percentile of Clinical Laboratory providers nationally.
62% of their billing comes from a single procedure code (U0003 — Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r).
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 824% in 2018
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $366.80 | $178.25 | 2.06x | $188.55 | $4.2M | 23.3K | 5 |
| 2015 | $398.95 | $198.48 | 2.01x | $200.47 | $1.9M | 9.7K | 15 |
| 2016 | $747.47 | $365.14 | 2.05x | $382.33 | $259.6K | 711 | 2 |
| 2017 | $198.46 | $114.03 | 1.74x | $84.43 | $126.9K | 1.1K | 10 |
| 2018 | $294.20 | $59.02 | 4.98x | $235.18 | $1.2M | 19.9K | 21 |
| 2019 | $111.93 | $44.60 | 2.51x | $67.33 | $5.2M | 117.1K | 27 |
| 2020 | $165.85 | $83.35 | 1.99x | $82.50 | $20.0M | 239.5K | 25 |
| 2021 | $143.99 | $57.12 | 2.52x | $86.87 | $22.7M | 396.8K | 33 |
| 2022 | $139.20 | $48.48 | 2.87x | $90.72 | $15.2M | 314.2K | 74 |
| 2023 | $73.15 | $24.86 | 2.94x | $48.29 | $5.3M | 211.7K | 99 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 555.7K | $45.9M | $82.56 | 2.34x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 213.3K | $5.3M | $24.90 | 3.05x |
| 87150 | Identification of organisms by genetic analysis, amplified probe technique | 145.0K | $5.2M | $35.74 | 2.21x |
| 81226 | Gene analysis (cytochrome p450, family 2, subfamily d, polypeptide 6) common variants | 7.1K | $3.1M | $442.18 | 1.93x |
| 87801 | Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 42.1K | $3.1M | $74.13 | 4.06x |
| 87481 | Detection test for candida species (yeast), amplified probe technique | 63.2K | $2.3M | $36.06 | 2.39x |
| 81225 | Gene analysis (cytochrome P450, family 2, subfamily C, polypeptide 19) common variants | 6.8K | $1.9M | $285.74 | 2.23x |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | 53.4K | $1.8M | $34.50 | 2.71x |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 18.2K | $665.8K | $36.53 | 2.28x |
| 87551 | Detection test by nucleic acid for mycobacteria species (bacteria), amplified probe technique | 13.8K | $658.0K | $47.58 | 2.02x |
| 87641 | Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 14.8K | $544.5K | $36.82 | 4.47x |
| 87471 | Detection by nucleic acid bartonella henselae and bartonella quintana (bacteria), amplified probe technique | 14.4K | $533.2K | $36.93 | 3.65x |
| 87500 | Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 14.3K | $525.1K | $36.62 | 2.47x |
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 14.0K | $519.0K | $37.09 | 2.16x |
| 81241 | Gene analysis (coagulation factor V) Leiden variant | 6.2K | $505.6K | $81.66 | 1.93x |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 3.0K | $426.9K | $141.92 | 2.01x |
| 81240 | Gene analysis (prothrombin, coagulation factor II) A variant | 6.2K | $407.2K | $65.75 | 1.27x |
| 81291 | Gene analysis (5, 10-methylenetetrahydrofolate reductase) common variants | 6.2K | $359.5K | $58.32 | 3.19x |
| 87636 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b | 2.2K | $304.7K | $141.28 | 2.02x |
| 87507 | Detection test for digestive tract pathogen | 269 | $140.7K | $522.87 | 2.15x |
This provider submits charges 2.48 times higher than what Medicare actually pays.
A markup ratio of 2.48x means for every $100 Medicare pays, this provider initially charges $248. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in VA for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Quest Diagnostics Nichols Institute, Inc. | Chantilly, VA | $37.8M | ✓ Clear |
| Vista Clinical Diagnostics Llc | Danville, VA | $35.2M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data